The current value of commercially available S1-derived SARS-CoV-2 antigens is approximately 7 USD μg−1, which is also prohibitive for most laboratories for large-scale screening of COVID-19-seropositive subjects. The gene discussed is PSMD1; the disease is COVID-19.